315 related articles for article (PubMed ID: 33115863)
1. Structure of High-Risk Papillomavirus 31 E6 Oncogenic Protein and Characterization of E6/E6AP/p53 Complex Formation.
Conrady MC; Suarez I; Gogl G; Frecot DI; Bonhoure A; Kostmann C; Cousido-Siah A; Mitschler A; Lim J; Masson M; Iftner T; Stubenrauch F; Travé G; Simon C
J Virol; 2020 Dec; 95(2):. PubMed ID: 33115863
[TBL] [Abstract][Full Text] [Related]
2. Structure of the E6/E6AP/p53 complex required for HPV-mediated degradation of p53.
Martinez-Zapien D; Ruiz FX; Poirson J; Mitschler A; Ramirez J; Forster A; Cousido-Siah A; Masson M; Vande Pol S; Podjarny A; Travé G; Zanier K
Nature; 2016 Jan; 529(7587):541-5. PubMed ID: 26789255
[TBL] [Abstract][Full Text] [Related]
3. Intracellular Analysis of the Interaction between the Human Papillomavirus Type 16 E6 Oncoprotein and Inhibitory Peptides.
Stutz C; Reinz E; Honegger A; Bulkescher J; Schweizer J; Zanier K; Travé G; Lohrey C; Hoppe-Seyler K; Hoppe-Seyler F
PLoS One; 2015; 10(7):e0132339. PubMed ID: 26151636
[TBL] [Abstract][Full Text] [Related]
4. Multiple regions of E6AP (UBE3A) contribute to interaction with papillomavirus E6 proteins and the activation of ubiquitin ligase activity.
Drews CM; Brimer N; Vande Pol SB
PLoS Pathog; 2020 Jan; 16(1):e1008295. PubMed ID: 31971989
[TBL] [Abstract][Full Text] [Related]
5. The E6AP binding pocket of the HPV16 E6 oncoprotein provides a docking site for a small inhibitory peptide unrelated to E6AP, indicating druggability of E6.
Zanier K; Stutz C; Kintscher S; Reinz E; Sehr P; Bulkescher J; Hoppe-Seyler K; Travé G; Hoppe-Seyler F
PLoS One; 2014; 9(11):e112514. PubMed ID: 25383876
[TBL] [Abstract][Full Text] [Related]
6. Association of papillomavirus E6 proteins with either MAML1 or E6AP clusters E6 proteins by structure, function, and evolutionary relatedness.
Brimer N; Drews CM; Vande Pol SB
PLoS Pathog; 2017 Dec; 13(12):e1006781. PubMed ID: 29281732
[TBL] [Abstract][Full Text] [Related]
7. Involvement of a cellular ubiquitin-protein ligase E6AP in the ubiquitin-mediated degradation of extensive substrates of high-risk human papillomavirus E6.
Matsumoto Y; Nakagawa S; Yano T; Takizawa S; Nagasaka K; Nakagawa K; Minaguchi T; Wada O; Ooishi H; Matsumoto K; Yasugi T; Kanda T; Huibregtse JM; Taketani Y
J Med Virol; 2006 Apr; 78(4):501-7. PubMed ID: 16482544
[TBL] [Abstract][Full Text] [Related]
8. Mapping the interactome of HPV E6 and E7 oncoproteins with the ubiquitin-proteasome system.
Poirson J; Biquand E; Straub ML; Cassonnet P; Nominé Y; Jones L; van der Werf S; Travé G; Zanier K; Jacob Y; Demeret C; Masson M
FEBS J; 2017 Oct; 284(19):3171-3201. PubMed ID: 28786561
[TBL] [Abstract][Full Text] [Related]
9. Stepwise multipolyubiquitination of p53 by the E6AP-E6 ubiquitin ligase complex.
Masuda Y; Saeki Y; Arai N; Kawai H; Kukimoto I; Tanaka K; Masutani C
J Biol Chem; 2019 Oct; 294(41):14860-14875. PubMed ID: 31492752
[TBL] [Abstract][Full Text] [Related]
10. A ubiquitin variant-based affinity approach selectively identifies substrates of the ubiquitin ligase E6AP in complex with HPV-11 E6 or HPV-16 E6.
Ebner FA; Sailer C; Eichbichler D; Jansen J; Sladewska-Marquardt A; Stengel F; Scheffner M
J Biol Chem; 2020 Oct; 295(44):15070-15082. PubMed ID: 32855237
[TBL] [Abstract][Full Text] [Related]
11. Solution structure analysis of the HPV16 E6 oncoprotein reveals a self-association mechanism required for E6-mediated degradation of p53.
Zanier K; ould M'hamed ould Sidi A; Boulade-Ladame C; Rybin V; Chappelle A; Atkinson A; Kieffer B; Travé G
Structure; 2012 Apr; 20(4):604-17. PubMed ID: 22483108
[TBL] [Abstract][Full Text] [Related]
12. Human Papillomavirus 16 (HPV-16), HPV-18, and HPV-31 E6 Override the Normal Phosphoregulation of E6AP Enzymatic Activity.
Thatte J; Banks L
J Virol; 2017 Nov; 91(22):. PubMed ID: 28835500
[TBL] [Abstract][Full Text] [Related]
13. Structure based identification and characterization of flavonoids that disrupt human papillomavirus-16 E6 function.
Cherry JJ; Rietz A; Malinkevich A; Liu Y; Xie M; Bartolowits M; Davisson VJ; Baleja JD; Androphy EJ
PLoS One; 2013; 8(12):e84506. PubMed ID: 24376816
[TBL] [Abstract][Full Text] [Related]
14. HPV16 E6 confers p53-dependent and p53-independent phenotypes in the epidermis of mice deficient for E6AP.
Shai A; Nguyen ML; Wagstaff J; Jiang YH; Lambert PF
Oncogene; 2007 May; 26(23):3321-8. PubMed ID: 17130828
[TBL] [Abstract][Full Text] [Related]
15. Peptide interactions stabilize and restructure human papillomavirus type 16 E6 to interact with p53.
Ansari T; Brimer N; Vande Pol SB
J Virol; 2012 Oct; 86(20):11386-91. PubMed ID: 22896608
[TBL] [Abstract][Full Text] [Related]
16. Human papillomavirus type 16 E6 induces self-ubiquitination of the E6AP ubiquitin-protein ligase.
Kao WH; Beaudenon SL; Talis AL; Huibregtse JM; Howley PM
J Virol; 2000 Jul; 74(14):6408-17. PubMed ID: 10864652
[TBL] [Abstract][Full Text] [Related]
17. Requirement of E6AP and the features of human papillomavirus E6 necessary to support degradation of p53.
Cooper B; Schneider S; Bohl J; Jiang Yh; Beaudet A; Vande Pol S
Virology; 2003 Feb; 306(1):87-99. PubMed ID: 12620801
[TBL] [Abstract][Full Text] [Related]
18. Felis catus papillomavirus type-2 E6 binds to E6AP, promotes E6AP/p53 binding and enhances p53 proteasomal degradation.
Altamura G; Power K; Martano M; Degli Uberti B; Galiero G; De Luca G; Maiolino P; Borzacchiello G
Sci Rep; 2018 Dec; 8(1):17529. PubMed ID: 30510267
[TBL] [Abstract][Full Text] [Related]
19. The role of E6AP in the regulation of p53 protein levels in human papillomavirus (HPV)-positive and HPV-negative cells.
Talis AL; Huibregtse JM; Howley PM
J Biol Chem; 1998 Mar; 273(11):6439-45. PubMed ID: 9497376
[TBL] [Abstract][Full Text] [Related]
20. Structural basis for hijacking of cellular LxxLL motifs by papillomavirus E6 oncoproteins.
Zanier K; Charbonnier S; Sidi AO; McEwen AG; Ferrario MG; Poussin-Courmontagne P; Cura V; Brimer N; Babah KO; Ansari T; Muller I; Stote RH; Cavarelli J; Vande Pol S; Travé G
Science; 2013 Feb; 339(6120):694-8. PubMed ID: 23393263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
